KRAS and acute lymphoblastic leukemia: The results showed that mutations were more common in NOTCH1(23/31,74.2%), PHF6(11/21,52.38%), KRAS(6/14,42.86%), JAK3(4/12,33.33%), CCND3(3/12,25%), JAK1(3/15,20%), STAT5B(2/10,20%), DNM2(2/10,20%) and EED(2/10,20%), these are common recurrent mutations in SET-CAN/NUP214 positive patients in T-ALL and ETP-ALL.